ArticleCanada communicable disease report = Releve des maladies transmissibles au Canada2018
Surveillance of laboratory exposures to human pathogens and toxins: Canada 2017.
Article in Canada communicable disease report = Releve des maladies transmissibles au Canada, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Surveillance of laboratory exposures to human pathogens and toxins, Canada, 2024.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2025Article
- Surveillance of laboratory exposures to human pathogens and toxins, Canada, 2023.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2025Article
- Canadian laboratory incidents with human pathogens and toxins: An overview of reports, 2016-2022.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2024Article
- Article
- Surveillance of laboratory exposures to human pathogens and toxins, Canada, 2022.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2023Article
- Surveillance of laboratory exposures to human pathogens and toxins, Canada, 2021.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2022Article
- Multivariate analyses of risk factors associated with laboratory exposure incidents.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2022Article
- Laboratory-acquired infections in Canada from 2016 to 2021.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2022Article
- Zika Virus Infection During Research Vaccine Development: Investigation of the Laboratory-Acquired InfectionFrontiers in cellular and infection microbiology · 2022Review
- Surveillance of laboratory exposures to human pathogens and toxins, Canada 2020.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2021Article
- Clinical Laboratory Biosafety Gaps: Lessons Learned from Past Outbreaks Reveal a Path to a Safer Future.Clinical microbiology reviews · 2021Review
- Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry-based identification of security-sensitive bacteria: Considerations for Canadian Bruker users.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2020Article
- Assessment of biorisk management systems in high containment laboratories, 18 countries in Europe, 2016 and 2017.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2020Article
- Surveillance of laboratory exposures to human pathogens and toxins: Canada 2018.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUnder Canada's
objectiveTo describe the laboratory exposure and laboratory-acquired infection incidents that occurred in Canada in 2017 by sector, human pathogens and toxins involved, number of affected persons, incident type and root causes.
methodsThe incidents included in the analysis occurred between January 1 and December 31, 2017. They were reported by laboratories with active licences to PHAC through the LINC surveillance system. Microsoft Excel 2010 was used for basic descriptive statistics.
resultsA total of 44 exposure and laboratory-acquired infection incidents were reported to the LINC in 2017. Compared by sector and their respective shares of licences, the number of incidents was highest in the academic and hospital sectors compared with government laboratories and private industry. Altogether 118 people were exposed for an average of 2.7 people per incident (range of 1-29). There were no reports of secondary exposure. Six exposure incidents (14%) led to "suspected" (n=5) or confirmed (n=1) cases of laboratory-acquired infection. Although overall, risk group (RG)2 human pathogens and toxins were involved in the majority of incidents (n=23; 52%),
conclusionThe incidence of laboratory exposure incidents was relatively low in 2017. The most common route of exposure was through inhalation and the most common root causes were problems with SOPs and human error. Since this is a new surveillance system, baseline estimates are still being established.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.